Opus Genetics (IRD) Competitors $0.80 -0.02 (-2.50%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.82 +0.02 (+2.24%) As of 04/15/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock IRD vs. PROC, EPRX, TLSA, ELUT, FATE, ALEC, MCRB, ENTA, FTLF, and XBITShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Procaps Group (PROC), Eupraxia Pharmaceuticals (EPRX), Tiziana Life Sciences (TLSA), Elutia (ELUT), Fate Therapeutics (FATE), Alector (ALEC), Seres Therapeutics (MCRB), Enanta Pharmaceuticals (ENTA), FitLife Brands (FTLF), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry. Opus Genetics vs. Procaps Group Eupraxia Pharmaceuticals Tiziana Life Sciences Elutia Fate Therapeutics Alector Seres Therapeutics Enanta Pharmaceuticals FitLife Brands XBiotech Opus Genetics (NASDAQ:IRD) and Procaps Group (NASDAQ:PROC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, community ranking, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability. Does the media refer more to IRD or PROC? In the previous week, Opus Genetics had 7 more articles in the media than Procaps Group. MarketBeat recorded 8 mentions for Opus Genetics and 1 mentions for Procaps Group. Procaps Group's average media sentiment score of 1.05 beat Opus Genetics' score of 0.24 indicating that Procaps Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Procaps Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, IRD or PROC? Procaps Group has higher revenue and earnings than Opus Genetics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpus Genetics$10.99M3.32-$9.99M-$2.15-0.37Procaps Group$409.92M0.26$42.54MN/AN/A Does the MarketBeat Community believe in IRD or PROC? Opus Genetics received 3 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 100.00% of users gave Opus Genetics an outperform vote while only 37.50% of users gave Procaps Group an outperform vote. CompanyUnderperformOutperformOpus GeneticsOutperform Votes6100.00% Underperform VotesNo VotesProcaps GroupOutperform Votes337.50% Underperform Votes562.50% Do institutionals & insiders hold more shares of IRD or PROC? 15.0% of Opus Genetics shares are held by institutional investors. 6.6% of Opus Genetics shares are held by company insiders. Comparatively, 19.9% of Procaps Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is IRD or PROC more profitable? Procaps Group has a net margin of 0.00% compared to Opus Genetics' net margin of -324.45%. Procaps Group's return on equity of 0.00% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Opus Genetics-324.45% -63.65% -56.94% Procaps Group N/A N/A N/A Which has more volatility and risk, IRD or PROC? Opus Genetics has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Procaps Group has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500. Do analysts prefer IRD or PROC? Opus Genetics currently has a consensus target price of $7.33, suggesting a potential upside of 814.38%. Given Opus Genetics' stronger consensus rating and higher possible upside, equities analysts plainly believe Opus Genetics is more favorable than Procaps Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Procaps Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryOpus Genetics beats Procaps Group on 9 of the 16 factors compared between the two stocks. Remove Ads Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.48M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.746.7921.6617.82Price / Sales3.32225.97373.3994.61Price / CashN/A65.6738.1534.64Price / Book0.365.866.474.00Net Income-$9.99M$141.86M$3.20B$247.23M7 Day Performance5.53%4.50%2.86%1.45%1 Month Performance-14.22%-12.65%-8.56%-6.24%1 Year PerformanceN/A-11.06%10.58%0.60% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics1.9731 of 5 stars$0.80-2.5%$7.33+814.4%N/A$36.48M$10.99M-0.7414PROCProcaps GroupN/A$0.95-40.3%N/A-63.5%$107.18M$409.92M0.004,900Positive NewsGap DownHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.366 of 5 stars$2.97+1.7%$10.50+253.5%+23.9%$105.87MN/A-4.1229Gap UpTLSATiziana Life Sciences1.2753 of 5 stars$0.90-4.6%N/A+62.0%$105.19MN/A0.008Positive NewsELUTElutia3.1254 of 5 stars$2.58-4.8%$9.00+248.8%-26.5%$105.10M$24.38M-0.99180Short Interest ↑Gap DownFATEFate Therapeutics3.4935 of 5 stars$0.91+20.8%$5.43+496.9%-80.1%$104.22M$13.63M-0.55550ALECAlector3.4925 of 5 stars$1.01-1.0%$3.50+246.5%-80.9%$100.08M$100.56M-0.59270Gap DownMCRBSeres Therapeutics3.0442 of 5 stars$0.57-10.6%$4.00+598.8%-25.2%$99.80M$126.33M-2.49330Gap DownENTAEnanta Pharmaceuticals4.0292 of 5 stars$4.64-1.9%$17.25+271.8%-68.1%$98.99M$66.59M-0.94160FTLFFitLife Brands4.2118 of 5 stars$10.47+0.7%$20.50+95.8%-15.5%$96.52M$64.47M12.3920High Trading VolumeXBITXBiotech1.1072 of 5 stars$3.15+9.8%N/A-66.2%$96.04M$4.01M-2.92100Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Procaps Group Alternatives Eupraxia Pharmaceuticals Alternatives Tiziana Life Sciences Alternatives Elutia Alternatives Fate Therapeutics Alternatives Alector Alternatives Seres Therapeutics Alternatives Enanta Pharmaceuticals Alternatives FitLife Brands Alternatives XBiotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRD) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IRD Stock Free IRD Stock Alerts